More Than Meets the Eye: Identifying Who Is at Risk for NASH

Slides:

Advertisements

Similar presentations

Non-alcoholic fatty liver disease and when to refer abnormal LFTs

Advertisements

V.E.I.L. Liver Cancer Prevention. 1. Vaccination Birth dose + 2 Universal for those not already chronics Screening pregnant women Catch up vaccination.

S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.

Weight Loss via Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis Gastroenterology 2015, /j.gastro

Ontario College of Family Physicians 51 st Annual Scientific Assembly Barry Lumb Fatty Liver Disease.

Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.

F ATTY L IVER Shahin Merat, M.D. Associate Professor of Medicine Digestive Disease Research Center, Tehran University of Medical Sciences, 8 th International.

Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.

Epidemiology of the Metabolic Syndrome in the USA Incidence ? Prevalence Distribution Control ? Incidence ? Prevalence Distribution Control ? Epidemiology.

THE PRESENCE OF HEPATIC STEATOSIS WHEN NO OTHER CAUSES FOR SECONDARY HEPATIC FAT ACCUMULATION NAFLD MAY PROGRESS TO CIRRHOSIS AND IS LIKELY AN IMPORTANT.

Diet, metabolic disease and cancers in mouse models Joe Nadeau Chair, Department of Genetics Case Western Reserve University

Simple Noninvasive Systems Predict long-term Outcome of Patients With NAFLD Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera.

Non-alcoholic Fatty Liver Disease

Hepatic Steatosis Chen-Yu Wang

Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.

Jun Yu,1,2 Joseph Jao-Yiu Sung,1,2 Henry Lik-Yuen Chan1,2

Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.

Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.

ALCOHOLIC LIVER DISEASE. Alcohol is one of the most common causes of chronic liver disease worldwide,In the UK, a unit of alcohol contains 8 g of ethanol.

Alcoholic liver disease and non-alcoholic fatty liver disease

Figure 1 Proposed risk stratification for patients with NAFLD

BY: Asmaa Alastal. wafaa hanouna. Salma abu taha. .Sara shaban

HCV & liver transplantation

Non-invasive assessment of

Guidelines for the diagnosis and management of Nonalcoholic Fatty Liver Disease (NAFLD): Update in 2012 Sameh M Fakhry MD, Msc, PhD Consultant of Gastroenterology,

Additional file 2 Total HCC cases N=39

A Review of the Critical Role of Imaging in Primary Liver Malignancy

Non-alcoholic steatohepatitis with positive ANA

Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis

HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.

Unraveling Clinical Developments in NASH

Starting Strong: Initial Evaluation of the Patient With HCV

Essential Updates in Atopic Dermatitis:

Recognizing and Staging the Severity of NASH: What Tools Do We Have?

PNPLA3 gene in liver diseases

The New England Journal of Medicine (378;12) March 22, 2018

Genetics and epigenetics of NAFLD and NASH

Optimizing Outcomes in the Management of GIST

Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease

Care of the Treatment-naive Patient With HCV/HIV Coinfection

Nat. Rev. Nephrol. doi: /nrneph

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Volume 149, Issue 2, Pages (August 2015)

Stephen A. Harrison, MD, FACP Clinical Gastroenterology and Hepatology

Lipid Clinic Challenge

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Intro: Biomarkers in RA

Example of algorithm for clinical assessment of patients at risk of non-alcoholic fatty liver disease Example of algorithm for clinical assessment.

Impact of metabolic risk factors on HCC

Hepatitis C: After the Diagnosis

Challenges in Severe Asthma

Care of Patients with Liver Problems

Reconciling Aging With HIV

Diagnosing Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome

Figure 1 NAFLD pathogenesis

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Volume 64, Issue 6, Pages (June 2016)

Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba Gastroenterology

Should we undertake surveillance for HCC in patients with NAFLD ??

Removing Barriers in the HCV Cascade of Care

The metabolomic window into hepatobiliary disease

The Building Blocks of Homocystinuria and Homocysteinemia Management

The Nurse View.

Order online at Carmen Ester1,3, Razvan Cerban1,3,, Razvan Iacob1,3, Speranta Iacob1,3, Andrei Sorop4, Lorand Savu6,

NAFLD and NASH in Europe and Canada

Foundations of Asthma.

Volume 135, Issue 6, Pages (December 2008)

Motor Fluctuations in PD

Presentation transcript:

More Than Meets the Eye: Identifying Who Is at Risk for NASH

NAFLD: Hepatic Manifestation of Metabolic Syndrome

NASH: From Steatosis to Cirrhosis

Prevalence of NAFLD Growing in Parallel With Obesity and Metabolic Syndrome

Patients at Risk for NASH How Do You Spot Them?

NASH in the Asia-Pacific Region

Case 1: 32-Year-Old Caucasian Man With Fatty Liver Seen In Ultrasound

Case 2: 60-Year-Old Hispanic Man With Well-Controlled Diabetes

Stratifying Risk for NASH It's Not All About Lab Values

The Genetic Component of NASH I148M PNPLA3 and Progressive Liver Disease

NASH Is a Phenotype Multi-Hit Pathogenesis

Ballooning: A Histologic Feature of NAFL

Natural History of NAFLD

HCC in NAFLD: Occurs In Patients With and Without Cirrhosis

NAFLD/NASH-Associated HCC Tumor Burden Is High

Ultrasound in NASH Not an Optimal Tool

NASH: Fast Becoming Leading Indication for Liver Transplantation in the United States

Progression of NAFLD Is Not Linear Fibrosis Is a Moving Target

NAFLD: Factors Related to Progression vs Regression

Using Clinical Parameters to Predict Outcomes

Biomarkers for NASH: What's In the Toolkit Now?

Why Is Assessment of Fibrosis vs NASH Important?

Patient- and Healthcare-Related Outcomes

Concluding Remarks

Abbreviations

Abbreviations (cont)